

# Global Avian Influenza Treatment Market - 2025 -2033

<https://marketpublishers.com/r/G96A9D09C51FEN.html>

Date: October 2025

Pages: 180

Price: US\$ 4,350.00 (Single User License)

ID: G96A9D09C51FEN

## Abstracts

### Industry Outlook

The global avian influenza treatment market reached US\$ 11.38 billion in 2023, with a rise of US\$ 12.43 billion in 2024, and is expected to reach US\$ 28.22 billion by 2033, growing at a CAGR of 9.6% during the forecast period 2025-2033.

The avian influenza treatment market is revolutionizing through rapid advancements in next-generation vaccines, such as recombinant and vector-based platforms, enabling quicker response to emerging strains. AI and genomics enhance early detection and outbreak prediction, allowing for targeted containment. Public-private partnerships and global funding initiatives are accelerating R&D and mass immunization efforts, especially in high-risk poultry regions.

### Market Dynamics: Drivers & Restraints

#### Driver: Emergence of Highly Mutating and Zoonotic Strains

The emergence of highly mutating and zoonotic strains of avian influenza is expected to significantly drive the growth of the avian influenza treatment market. As the virus continues to evolve rapidly, it raises serious public health concerns. For instance, the H5N1 strain, which has been detected in both wild birds and poultry, has also been found in humans and even in dairy cattle in recent outbreaks. These developments heighten the urgency for more effective antiviral therapies, vaccines, and diagnostic tools.

For instance, the 2024 outbreak of HPAI H5N1 in U.S. dairy cattle highlighted how the virus can cross species barriers, exposing critical gaps in surveillance and biosecurity. This incident emphasized the need for integrated health approaches and accelerated

research to better control and treat such zoonotic infections.

Governments and health organizations around the world are ramping up surveillance and preparedness strategies, leading to increased funding and the fast-tracking of treatment research. The unpredictability and severity of these mutations not only amplify demand for existing solutions but also open the door for new players and innovations in the market, making this a key growth driver in the coming years.

#### Restraint: Rapid Virus Mutation and Antigenic Drift

Rapid virus mutation and antigenic drift could significantly hamper the avian influenza treatment market by undermining the effectiveness of existing vaccines and antiviral drugs. As the avian influenza virus constantly changes its genetic makeup, especially through antigenic drift, the proteins on its surface mutate enough to evade immune responses. For instance, a vaccine designed to target the H5N1 strain might not offer protection against a mutated H5N6 or H7N9 variant.

Similarly, antiviral treatments can lose potency as the virus develops resistance over time. These frequent changes increase the complexity and cost of research and development, delay regulatory approvals, and create uncertainty for manufacturers and healthcare providers. As a result, while the need for treatment remains high, the unpredictable nature of the virus can slow market growth and limit the long-term viability of current therapeutic options.

#### Segmentation Analysis

The global avian influenza treatment market is segmented based on virus strain, treatment type, end-user, and region.

#### Treatment Type:

The antiviral drugs segment is expected to have 44.4% of the avian influenza treatment market share.

The antiviral drugs segment is expected to hold a dominant position in the avian influenza treatment market due to their critical role in managing and controlling the spread of the virus, especially during outbreaks. Antiviral drugs offer a more immediate line of defense by reducing the severity and duration of the illness. Drugs like oseltamivir (Tamiflu) and zanamivir (Relenza) have been widely used to treat various

strains of avian influenza, particularly in high-risk populations and during pandemic preparedness efforts.

Additionally, the growing incidence of zoonotic transmission to humans and the global emphasis on stockpiling antivirals for emergency use have further boosted demand. With governments and healthcare systems prioritizing quick-response treatment options and ongoing R&D into broad-spectrum antivirals, this segment is well-positioned to lead the market in the foreseeable future.

For instance, in May 2025, the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) announced the development of a next-generation universal vaccine platform called Generation Gold Standard, which utilizes a beta-propiolactone (BPL)-inactivated, whole-virus approach. This initiative marks a significant move toward greater transparency, improved efficacy, and enhanced pandemic preparedness. It supports the NIH's internal efforts to develop universal vaccines targeting both influenza and coronaviruses, including vaccine candidates BPL-1357 and BPL-24910. These vaccines are designed to offer broad-spectrum protection against multiple pandemic-prone viruses such as the H5N1 avian influenza strain and coronaviruses.

### Geographical Analysis

The North America avian influenza treatment market was valued at 39.6% market share in 2024

North America holds a dominant position in the global avian influenza treatment market due to several key factors. The region benefits from well-established healthcare infrastructure and advanced research facilities that support the development and distribution of effective antiviral drugs and vaccines. Strong government initiatives and significant funding for infectious disease control further boost market growth.

Additionally, North America's robust surveillance systems enable early detection and rapid response to avian influenza outbreaks, increasing demand for timely treatments. The presence of major pharmaceutical companies and ongoing investment in innovative therapies also contribute to the region's leadership in this market. The supportive government initiatives and funding are expected to further expand the region's market share in the global market.

For instance, in January 2025, the Department of Health and Human Services

announced the allocation of approximately \$306 million to support the federal response to the H5N1 bird flu. Out of this, the Administration for Strategic Preparedness and Response will distribute nearly \$183 million to bolster regional, state, and local preparedness efforts. This includes \$90 million for the Hospital Preparedness Program, \$10 million for the National Emerging Special Pathogens Training and Education Center, \$26 million for the Regional Emerging Special Pathogen Treatment Centers, \$43 million dedicated to Avian Influenza Preparedness and Response Activities at the Special Pathogen Treatment Centers, and \$14 million for the National Disaster Medical System.

## Major Players

The major players in the avian influenza treatment market include F. Hoffmann-La Roche Ltd, GSK plc, CSL, Boehringer Ingelheim International GmbH, Ceva, Zoetis Services LLC, Merck & Co., Inc., among others.

## Key Developments

In May 2025, Cocrystal Pharma, Inc. (Nasdaq: COCP) announced promising results from a recent virology study, revealing that its novel broad-spectrum influenza PB2 inhibitor, CC-42344, demonstrated strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain.

In January 2025, Traws Pharma completed Phase I clinical trials of tioxavir marboxil, a single-dose treatment for H5N1 bird flu. The randomized, double-blind, placebo-controlled study assessed the drug's safety, pharmacokinetics (PK), pharmacodynamics (PD), and tolerability in healthy, influenza-negative adults.

The global avian influenza treatment market report delivers a detailed analysis with 56 key tables, more than 53 visually impactful figures, and 195 pages of expert insights, providing a complete view of the market landscape.

## Contents

### **1. MARKET INTRODUCTION AND SCOPE**

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

### **2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS**

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Product Type
- 2.4. Snippet by Ingredients
- 2.5. Snippet by Form
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

### **3. DYNAMICS**

- 3.1. Impacting Factors
  - 3.1.1. Drivers
    - 3.1.1.1. Emergence of Highly Mutating and Zoonotic Strains
    - 3.1.1.2. Shift Toward Next-Generation Vaccines
  - 3.1.2. Restraints
    - 3.1.2.1. Rapid Virus Mutation and Antigenic Drift
    - 3.1.2.2. Cold Chain and Infrastructure Challenges
  - 3.1.3. Opportunity
    - 3.1.3.1. Expansion in Emerging Poultry Markets
    - 3.1.3.2. Development of Universal or Multivalent Avian Influenza Vaccines
  - 3.1.4. Impact Analysis

### **4. GLOBAL AVIAN INFLUENZA TREATMENT MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK**

- 4.1. Market Leaders and Pioneers
  - 4.1.1. Emerging Pioneers and Prominent Players
  - 4.1.2. Established leaders with largest largest-selling Brand
  - 4.1.3. Market leaders with established products & Services

- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
  - 4.3.1. North America
  - 4.3.2. Europe
  - 4.3.3. Asia Pacific
  - 4.3.4. South America
  - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Force Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Pricing Analysis and Price Dynamics

## **5. GLOBAL AVIAN INFLUENZA TREATMENT MARKET: BY VIRUS STRAIN**

- 5.1. Introduction
  - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
  - 5.1.2. Market Attractiveness Index, By Virus Strain
- 5.2. H5N1\*
  - 5.2.1. Introduction
  - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. H7N9
- 5.4. H10N8
- 5.5. H5N6
- 5.6. H9N2
- 5.7. H6N1
- 5.8. Others

## **6. GLOBAL AVIAN INFLUENZA TREATMENT MARKET: BY TREATMENT TYPE**

- 6.1. Introduction
  - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 6.1.2. Market Attractiveness Index, By Treatment Type
- 6.2. Antiviral Drugs\*
  - 6.2.1. Introduction
  - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  - 6.2.3. Oseltamivir (Tamiflu)

- 6.2.4. Zanamivir (Relenza)
- 6.2.5. Peramivir (Rapivab)
- 6.2.6. Others
- 6.3. Vaccines
- 6.4. Antibiotics
- 6.5. Immunoglobulins
- 6.6. Others

## **7. GLOBAL AVIAN INFLUENZA TREATMENT MARKET: BY END-USER**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 7.1.2. Market Attractiveness Index, By End-User
- 7.2. Hospitals & Clinics\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Government Health Agencies
- 7.4. Research Institutes
- 7.5. Others

## **8. GLOBAL AVIAN INFLUENZA TREATMENT MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  - 8.1.2. Market Attractiveness Index, By Region
- 8.2. North America
  - 8.2.1. Introduction
  - 8.2.2. Key Region-Specific Dynamics
  - 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
  - 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 8.2.6.1. U.S.
    - 8.2.6.2. Canada
    - 8.2.6.3. Mexico
- 8.3. Europe
  - 8.3.1. Introduction
  - 8.3.2. Key Region-Specific Dynamics

- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.6.1. Germany
  - 8.3.6.2. U.K.
  - 8.3.6.3. France
  - 8.3.6.4. Spain
  - 8.3.6.5. Italy
  - 8.3.6.6. Rest of Europe
- 8.4. South America
  - 8.4.1. Introduction
  - 8.4.2. Key Region-Specific Dynamics
  - 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
  - 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 8.4.6.1. Brazil
    - 8.4.6.2. Argentina
    - 8.4.6.3. Rest of South America
- 8.5. Asia-Pacific
  - 8.5.1. Introduction
  - 8.5.2. Key Region-Specific Dynamics
  - 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
  - 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 8.5.6.1. China
    - 8.5.6.2. India
    - 8.5.6.3. Japan
    - 8.5.6.4. South Korea
    - 8.5.6.5. Rest of Asia-Pacific
- 8.6. Middle East and Africa
  - 8.6.1. Introduction
  - 8.6.2. Key Region-Specific Dynamics
  - 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Virus Strain
  - 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  - 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

## **9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING**

- 9.1. Competitive Overview and Key Market Players
- 9.2. Market Share Analysis and Positioning Matrix
- 9.3. Strategic Partnerships, Mergers & Acquisitions
- 9.4. Key Developments in Product Portfolios and Innovations
- 9.5. Company Benchmarking

## **10. COMPANY PROFILES**

- 10.1. F. Hoffmann-La Roche Ltd\*
  - 10.1.1. Company Overview
  - 10.1.2. Product Portfolio
    - 10.1.2.1. Product Description
    - 10.1.2.2. Product Key Performance Indicators (KPIs)
    - 10.1.2.3. Historic and Forecasted Product Sales
    - 10.1.2.4. Product Sales Volume
  - 10.1.3. Financial Overview
    - 10.1.3.1. Company Revenue
    - 10.1.3.2. Geographical Revenue Shares
    - 10.1.3.3. Revenue Forecasts
  - 10.1.4. Key Developments
    - 10.1.4.1. Mergers & Acquisitions
    - 10.1.4.2. Key Product Development Activities
    - 10.1.4.3. Regulatory Approvals, etc.
    - 10.1.4.4. SWOT Analysis
- 10.2. GSK plc
- 10.3. CSL
- 10.4. Boehringer Ingelheim International GmbH
- 10.5. Ceva
- 10.6. Zoetis Services LLC
- 10.7. Merck & Co., Inc. (LIST NOT EXHAUSTIVE)

## **11. ASSUMPTIONS AND RESEARCH METHODOLOGY**

- 11.1. Data Collection Methods
- 11.2. Data Triangulation
- 11.3. Forecasting Techniques
- 11.4. Data Verification and Validation

## **12. APPENDIX**

12.1. About Us and Services

12.2. Contact Us

## List Of Tables

### LIST OF TABLES

- Table 1 Global Avian Influenza Treatment Market Value, By Virus Strain, 2025, 2029 & 2033 (US\$ Billion)
- Table 2 Global Avian Influenza Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)
- Table 3 Global Avian Influenza Treatment Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)
- Table 4 Global Avian Influenza Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)
- Table 5 Global Avian Influenza Treatment Market Value, By Virus Strain, 2025, 2029 & 2033 (US\$ Billion)
- Table 6 Global Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)
- Table 7 Global Avian Influenza Treatment Market Value, By Treatment Type, 2025, 2029 & 2033 (US\$ Billion)
- Table 8 Global Avian Influenza Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)
- Table 9 Global Avian Influenza Treatment Market Value, By End-User, 2025, 2029 & 2033 (US\$ Billion)
- Table 10 Global Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)
- Table 11 Global Avian Influenza Treatment Market Value, By Region, 2025, 2029 & 2033 (US\$ Billion)
- Table 12 Global Avian Influenza Treatment Market Value, By Region, 2022-2033 (US\$ Billion)
- Table 13 North America Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)
- Table 14 North America Avian Influenza Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)
- Table 15 North America Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)
- Table 16 North America Avian Influenza Treatment Market Value, By Country, 2022-2033 (US\$ Billion)
- Table 17 Asia-Pacific Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)
- Table 18 Asia-Pacific Avian Influenza Treatment Market Value, By Treatment Type,

2022-2033 (US\$ Billion)

Table 19 Asia-Pacific Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 20 Asia-Pacific Avian Influenza Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 21 Europe Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)

Table 22 Europe Avian Influenza Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 23 Europe Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 24 Europe Avian Influenza Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 25 South America Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)

Table 26 South America Avian Influenza Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 27 South America Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 28 South America Avian Influenza Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 29 Middle East and Africa Avian Influenza Treatment Market Value, By Virus Strain, 2022-2033 (US\$ Billion)

Table 30 Middle East and Africa Avian Influenza Treatment Market Value, By Treatment Type, 2022-2033 (US\$ Billion)

Table 31 Middle East and Africa Avian Influenza Treatment Market Value, By End-User, 2022-2033 (US\$ Billion)

Table 32 Middle East and Africa Avian Influenza Treatment Market Value, By Country, 2022-2033 (US\$ Billion)

Table 33 F. Hoffmann-La Roche Ltd: Overview

Table 34 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 35 F. Hoffmann-La Roche Ltd: Key Developments

Table 36 GSK plc: Overview

Table 37 GSK plc: Product Portfolio

Table 38 GSK plc: Key Developments

Table 39 CSL: Overview

Table 40 CSL: Product Portfolio

Table 41 CSL: Key Developments

Table 42 Boehringer Ingelheim International GmbH: Overview

Table 43 Boehringer Ingelheim International GmbH: Product Portfolio  
Table 44 Boehringer Ingelheim International GmbH: Key Developments  
Table 45 Ceva: Overview  
Table 46 Ceva: Product Portfolio  
Table 47 Ceva: Key Developments  
Table 48 Zoetis Services LLC: Overview  
Table 49 Zoetis Services LLC: Product Portfolio  
Table 50 Zoetis Services LLC: Key Developments  
Table 51 Merck & Co., Inc.: Overview  
Table 52 Merck & Co., Inc.: Product Portfolio  
Table 53 Merck & Co., Inc.: Key Developments

## List Of Figures

### LIST OF FIGURES

Figure 1 Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 2 Global Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 3 Global Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 4 Global Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 5 Global Avian Influenza Treatment Market Share, By Region, 2024 & 2033 (%)

Figure 6 Global Avian Influenza Treatment Market Y-o-Y Growth, By Virus Strain, 2023-2033 (%)

Figure 7 H5N1 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 8 H7N9 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 9 H10N8 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 10 H5N6 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 11 H9N2 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 12 H6N1 Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 13 Others Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 14 Global Avian Influenza Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2033 (%)

Figure 15 Antiviral Drugs Treatment Type in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 16 Vaccines Treatment Type in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 17 Antibiotics Treatment Type in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 18 Immunoglobulins Treatment Type in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 19 Others Treatment Type in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 20 Global Avian Influenza Treatment Market Y-o-Y Growth, By End-User, 2023-2033 (%)

Figure 21 Hospitals & Clinics End-User in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 22 Government Health Agencies End-User in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 23 Research Institutes End-User in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 24 Others End-User in Global Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 25 Global Avian Influenza Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)

Figure 26 North America Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 27 North America Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 28 North America Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 29 North America Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 30 North America Avian Influenza Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 31 Asia-Pacific Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 32 Asia-Pacific Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 33 Asia-Pacific Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 34 Asia-Pacific Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 35 Asia-Pacific Avian Influenza Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 36 Europe Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 37 Europe Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 38 Europe Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 39 Europe Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 40 Europe Avian Influenza Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 41 South America Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 42 South America Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 43 South America Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 44 South America Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 45 South America Avian Influenza Treatment Market Share, By Country, 2024 & 2033 (%)

Figure 46 Middle East and Africa Avian Influenza Treatment Market Value, 2022-2033 (US\$ Billion)

Figure 47 Middle East and Africa Avian Influenza Treatment Market Share, By Virus Strain, 2024 & 2033 (%)

Figure 48 Middle East and Africa Avian Influenza Treatment Market Share, By Treatment Type, 2024 & 2033 (%)

Figure 49 Middle East and Africa Avian Influenza Treatment Market Share, By End-User, 2024 & 2033 (%)

Figure 50 F. Hoffmann-La Roche Ltd: Financials

Figure 51 GSK plc: Financials

Figure 52 CSL: Financials

Figure 53 Boehringer Ingelheim International GmbH: Financials

Figure 54 Ceva: Financials

Figure 55 Zoetis Services LLC: Financials

Figure 56 Merck & Co., Inc.: Financials

## I would like to order

Product name: Global Avian Influenza Treatment Market - 2025 -2033

Product link: <https://marketpublishers.com/r/G96A9D09C51FEN.html>

Price: US\$ 4,350.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G96A9D09C51FEN.html>